AML
Showing NaN - NaN of 9
Hematologic Malignancy, AML, ALL Trial in Australia, United States (Tagraxofusp, Fludarabine, Cytarabine)
Not yet recruiting
- Hematologic Malignancy
- +10 more
- Tagraxofusp
- +8 more
-
Los Angeles, California
- +28 more
Jul 26, 2022
AML Trial in Puerto Rico, United States (Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only))
Completed
- AML
- Cytarabine (Phase 1 only)
- +3 more
-
Los Angeles, California
- +16 more
Feb 22, 2022
Myeloid Leukemias, AML, Leukemia Trial in Philadelphia (Rapamycin, Mitoxantrone, Etoposide, Cytarabine, Rapamycin + MEC)
Completed
- Myeloid Leukemias
- +3 more
- Rapamycin, Mitoxantrone, Etoposide, Cytarabine
- Rapamycin + MEC
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania Abramson Cancer Center
Jul 10, 2019
Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia Trial in Philadelphia (radiation, biological, drug)
Terminated
- Hematologic Malignancy
- +11 more
- Total Body Irradiation (TBI)
- +5 more
-
Philadelphia, PennsylvaniaThomas Jefferson University
Oct 19, 2016
CML, AML, MDS Trial in Philadelphia (Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells, Observation Arm)
Completed
- CML
- +6 more
- Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells
- Observation Arm
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Aug 17, 2016
AML, Acute Myeloid Leukemia Trial in Philadelphia (Bexarotene)
Completed
- AML
- Acute Myeloid Leukemia
-
Philadelphia, PennsylvaniaAbramson Cancer Center of University of Pennsylvania
Jun 7, 2016